Polymeric endoaortic paving (PEAP) is a process by which a polymer is endovascularly delivered and thermoformed to coat or “pave” the lumen of the aorta. This method may offer an improvement to conventional endoaortic therapy in allowing conformal graft application with reduced risk of endoleak and customization to complex patient geometries. Polycaprolactone (PCL)/polyurethane (PU) blends of various blend ratios were assessed as a potential material for PEAP by characterizing their mechanical, thermoforming, and degradation properties. Biaxial tension testing revealed that the blends' stiffness is similar to that of aortic tissue, is higher for blends with more PCL content, and may be affected by thermoforming and degradation. Tubes of blends were able to maintain a higher diameter increase after thermoforming at higher PCL content and higher heating temperatures; 50/50 blend tubes heated to 55°C were able to maintain 90% of the diameter increase applied. Delamination forces of the blends ranged from 41 to 235 N/m2. In a Pseudomonas lipase solution, the 50/50 blend had a 94% lower degradation rate than pure PCL, and the 10/90 blend exhibited no degradation. These results indicate that PEAP, consisting of a PCL/PU blend, may be useful in developing the next generation of endoaortic therapy.

The preferred method to treat abdominal aortic aneurysms (AAAs) is endovascular repair with a stent-graft (EVAR). Although EVAR is fairly successful, there are several challenges to address, which include patient ineligibility due to complex anatomy and long-term failure due to migration and endoleak. Drug treatments that reduce or halt AAA growth are also currently under investigation [1].